The kidney’s proximal tubule features two distinct segments responsible for glucose reabsorption: the S1 and S2 segments predominantly reabsorb glucose through SGLT2, handling approximately 97% of the filtered glucose load. Meanwhile, the S3 segment engages SGLT1 to reclaim the remaining glucose. While selective SGLT2 inhibitors like dapagliflozin primarily target these early segments, dual inhibition that includes SGLT1 presents an opportunity to influence downstream effects more comprehensively. This approach, until recently, was explored primarily for its potential in diabetes management. However, its implications for blood pressure regulation and renal protection have drawn significant attention owing to the complex interplay between sodium handling, glucose reabsorption, and vascular health.

Salt-sensitive hypertension, a prevalent condition affecting nearly half of hypertensive patients, is characterized by heightened blood pressure responses to excessive dietary salt intake. This pathology not only exacerbates cardiovascular risk but also accelerates kidney damage, ultimately contributing to chronic kidney disease (CKD) progression and renal failure. To model this condition experimentally, researchers utilized established rodent models subjected to high salt diets, mimicking the pathophysiological mechanisms underlying human salt-sensitive hypertension. In this model, the effects of selective SGLT2 inhibition were rigorously compared with those of dual SGLT1/2 inhibition through pharmacological agents dapagliflozin and sotagliflozin, respectively.

Findings demonstrated that while both dapagliflozin and sotagliflozin notably mitigated the severity of salt-induced hypertensive pathology, the dual SGLT1/2 inhibitor produced a more pronounced reduction in mean arterial pressure. This superior efficacy was accompanied by a striking attenuation in kidney injury markers, underscoring the enhanced renal protective capacity of dual inhibition. Interestingly, neither treatment exerted significant effects on blood pressure under normal salt intake, emphasizing the salt-dependent nature of their therapeutic impact. These results suggest a targeted mechanism by which dual inhibition modulates renal sodium and glucose handling, reducing volume overload and subsequent vascular strain.

Further mechanistic insights emerged as researchers observed that sotagliflozin uniquely influenced urinary electrolyte excretion. The drug enhanced sodium and chloride excretion more effectively than dapagliflozin, indicating a potentiation of natriuresis. Additionally, fractional glucose excretion nearly doubled with dual inhibition, signifying a more robust blockade of glucose reabsorption pathways throughout the proximal tubule segments. Despite these metabolic shifts, both drugs preserved overall kidney function, reassuring the renal safety profile of this therapeutic approach. The nuanced metabolic modulation was particularly evident in region-specific alterations in renal lipid metabolism and inflammatory signaling pathways, hallmarks of hypertension-induced kidney injury.

At the molecular level, SGLT2 inhibition demonstrated selective modulation of renal metabolic processes, especially affecting lipid utilization and inflammatory mediators within kidney tissues. These alterations hold substantial significance given the kidney’s high metabolic demands and the role of lipotoxicity in chronic kidney disease progression. By attenuating inflammatory signaling cascades, dual SGLT1/2 inhibition may quell the chronic low-grade inflammation that characterizes hypertensive kidney damage. Such molecular effects complement hemodynamic improvements, creating a multifactorial approach to renal and cardiovascular protection.

Olha Kravtsova, PhD, from the University of South Florida and the lead investigator of the study, emphasized the translational potential of these findings. The preclinical evidence supports broadening the clinical application of dual SGLT1/2 inhibitors beyond their conventional roles in heart failure and diabetes patients. Particularly for individuals grappling with salt-sensitive hypertension—a condition notoriously resistant to conventional antihypertensives—this therapeutic avenue heralds a promising alternative. Moreover, the newly uncovered metabolic pathways delineate exciting opportunities for further research, potentially unearthing novel drug targets centered on lipid metabolism and inflammatory modulation within the kidney.

The clinical implications extend beyond mere blood pressure control. By effectively lowering salt-induced hypertension and simultaneously reducing renal injury, dual SGLT1/2 inhibitors could alter the current management paradigms for chronic kidney disease. Given that hypertension remains a leading cause of CKD worldwide, a therapy that addresses the root contributors at a renal tubular level fits into a precision medicine framework. In light of these findings, nephrologists and cardiologists alike may soon consider the benefits of such combination inhibitors in comprehensive cardiovascular and renal care.

Intriguingly, the differential impact of SGLT1 versus SGLT2 blockade on sodium handling sheds light on the physiological role of proximal tubular segments in hypertensive pathophysiology. Whereas SGLT2 inhibition primarily affects early sodium and glucose reabsorption, the addition of SGLT1 blockade—localized to the more distal S3 segment—increases sodium excretion synergistically. This layered approach to disrupting sodium reabsorption pathways suggests a sophisticated mechanism for controlling volume overload and hypertension. These insights may also inform future drug development, guiding the design of agents with tailored segmental specificity.

Despite the promising outcomes, the study underscores the necessity for cautious progression toward human trials. Translational hurdles remain, given species differences in renal transporter expression and function. Nevertheless, the consistency of salt-sensitive hypertension mechanisms across mammals furnishes a robust preclinical foundation. The research presented at ASN Kidney Week 2025 invites the nephrology community to reassess the therapeutic landscape and fosters optimism for refined interventions in salt-related hypertensive and renal disorders.

The study titled “Dual SGLT1/2 Inhibition Attenuates Salt-Sensitive Hypertension and Kidney Injury More Effectively than SGLT2 Inhibition” represents a pivotal step in the nuanced understanding of renal glucose and sodium transport and its systemic effects. As researchers continue to unravel these complex interactions, the potential to transform clinical practice becomes increasingly tangible. This research signals a paradigm shift from singular to dual transporter inhibition, reflecting a comprehensive strategy to mitigate the multifactorial nature of hypertension and renal injury.

In conclusion, the dual inhibition of SGLT1 and SGLT2 by agents such as sotagliflozin offers a promising avenue for not only glycemic control but also for significant cardiovascular and renal protection. The findings from this rodent model study suggest that targeting multiple transporters in the kidney proximal tubule can more effectively suppress salt-sensitive hypertension and renal damage than current selective therapies. As new avenues open for addressing the metabolic and inflammatory underpinnings of hypertensive kidney disease, this line of research holds transformative potential for patients worldwide.

Join approximately 12,000 kidney specialists and healthcare professionals at ASN Kidney Week 2025 in Houston, TX, November 5–9, for the latest scientific discussions and updates in nephrology, including advances such as these that redefine kidney disease management. This global meeting remains a pivotal platform to exchange innovation, knowledge, and insight among leading experts aiming to improve patient outcomes in renal medicine.

Subject of Research: Effects of dual SGLT1/2 inhibition versus selective SGLT2 inhibition on salt-sensitive hypertension and kidney injury in a rat model
Article Title: Dual SGLT1/2 Inhibition Attenuates Salt-Sensitive Hypertension and Kidney Injury More Effectively than SGLT2 Inhibition
News Publication Date: November 7, 2025
Web References: www.asn-online.org
Keywords: Sodium-glucose co-transporter, SGLT1, SGLT2, salt-sensitive hypertension, kidney injury, dapagliflozin, sotagliflozin, proximal tubule, natriuresis, renal metabolism, lipid metabolism, inflammatory signaling

The CMCA, originally founded in 2020 under the auspices of Saint Luke’s Mid America Heart Institute in Kansas City, Missouri, emerged from an innovative vision led by Mikhail Kosiborod, M.D. It sought to challenge traditional fragmented care paradigms where Type 2 diabetes, pre-diabetes, and cardiovascular conditions have often been addressed in isolation. Instead, CMCA introduced a novel model emphasizing comprehensive risk reduction through coordinated, team-based care tailored to each patient’s unique clinical profile.

This approach is grounded in the recognition that cardiometabolic disorders share overlapping pathophysiological mechanisms, including insulin resistance, systemic inflammation, and endothelial dysfunction, which collectively exacerbate morbidity and mortality risks. By adopting a holistic treatment framework, the CMCA’s protocol prioritizes simultaneous management of glycemic control, lipid abnormalities, hypertension, and renal function—all critical determinants in the trajectory of these diseases.

Clinical outcomes attained under this integrated care model have been compelling. Data accrued over five years from the CMCA’s consortium of 22 member centers demonstrated statistically significant improvements in guideline-directed medical therapy adherence and reductions in adverse cardiovascular events. Such evidence underscores the efficacy of a standardized protocol that transcends traditional specialty silos, fostering seamless communication between endocrinologists, cardiologists, nephrologists, and primary care providers.

The acquisition of CMCA’s assets by the AHA is set to amplify these advances on a national scale. Leveraging the AHA’s expansive infrastructure and influence, the initiative will evolve into a Cardiovascular-Kidney-Metabolic Center of Excellence certification program. This program will provide a rigorous framework for clinical best practices and facilitate dissemination of CMCA’s comprehensive care protocols, thereby enhancing consistency and quality across diverse healthcare environments.

Melissa Magwire, RN, MSN, CDCES, director of the CMCA program, reflected on the transition: “The alignment with the American Heart Association empowers us to extend the reach of our care model exponentially. Our members’ dedication has propelled meaningful progress in managing cardiometabolic diseases, and now, with greater resources, we can impact outcome trajectories for a vastly larger patient population.”

Moreover, the integration embodies a forward-thinking response to the escalating prevalence of cardiometabolic conditions, which constitute global public health challenges due to their rising incidence and associated healthcare burdens. The synergy between the CMCA’s evidence-based care model and the AHA’s longstanding commitment to cardiovascular and stroke research positions this collaboration at the forefront of efforts to curb disease progression through prevention and early intervention.

Scientific leadership from both entities will drive the continual refinement of clinical protocols, incorporating emerging findings from cardiovascular, renal, and metabolic medicine. This dynamic feedback loop ensures that patient management strategies remain aligned with the latest therapeutic advances, including precision medicine approaches and novel pharmacotherapies designed to target multifactorial disease processes.

Importantly, the patient-centered care ethos anchors the collaboration’s vision. Recognizing that chronic disease management is inherently complex and requires sustained engagement, the model incorporates multidisciplinary teams featuring physicians, nurses, dietitians, diabetes educators, and behavioral specialists. This structure facilitates tailored education, adherence support, and psychosocial interventions critical to long-term success.

Mariell Jessup, M.D., FAHA, Chief Science & Medical Officer of the American Heart Association, emphasized the transformational potential of this union: “By combining the American Heart Association’s scientific rigor with the CMCA’s pioneering clinical model, we unlock unprecedented opportunities to revolutionize cardiometabolic care. This collaborative effort is uniquely positioned to mitigate disease burdens and extend healthy life spans.”

As CMCA leadership transitions to key roles within the AHA, the alliance’s foundational principles will persist and evolve. The commitment to data-driven quality improvement, standardized care delivery, and multidisciplinary team collaboration remains central, fostering a new paradigm that other healthcare systems are poised to emulate.

This acquisition stands as a testament to the power of collaborative innovation in healthcare. By breaking down traditional barriers between specialties and addressing complex chronic illnesses through an integrated lens, the combined efforts of the AHA and CMCA illuminate a future where comprehensive, patient-centered cardiometabolic care is the standard rather than the exception.

Subject of Research: Integrated care models for cardiometabolic disease encompassing cardiovascular, kidney, and metabolic system management.

Article Title: The American Heart Association Joins Forces with Cardiometabolic Center Alliance to Pioneer Integrated Cardiometabolic Care

News Publication Date: October 1, 2025

Web References:
– https://heart.org/en
– https://x.com/HeartNews
– https://x.com/American_Heart

Keywords: Cardiometabolic disease, integrated care, cardiovascular disease, Type 2 diabetes, kidney disease, patient-centered care, multidisciplinary team, clinical outcomes, guideline-directed medical therapy, preventive cardiology, chronic disease management, healthcare innovation